150 related articles for article (PubMed ID: 16617562)
1. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
[TBL] [Abstract][Full Text] [Related]
2. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
4. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
[TBL] [Abstract][Full Text] [Related]
6. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
8. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
9. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
11. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
[TBL] [Abstract][Full Text] [Related]
14. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Dorn J; Schmitt M; Kates R; Schmalfeldt B; Kiechle M; Scorilas A; Diamandis EP; Harbeck N
Clin Cancer Res; 2007 Mar; 13(6):1742-8. PubMed ID: 17363527
[TBL] [Abstract][Full Text] [Related]
15. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
16. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
17. Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series.
Sprem M; Babić D; Abramić M; Vrhovec I; Skrk J; Milicić D; Ambriović Ristov A; Kalafatić D; Osmak M
Croat Med J; 2001 Dec; 42(6):624-9. PubMed ID: 11740844
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM
Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465
[TBL] [Abstract][Full Text] [Related]
19. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
